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DOI 10.1186/s12881-015-0183-0RESEARCH ARTICLE Open AccessNovel VPS13B Mutations in Three Large
Pakistani Cohen Syndrome Families Suggests
a Baloch Variant with Autistic-Like Features
Muhammad Arshad Rafiq1,20†, Claire S Leblond2,21†, Muhammad Arif Nadeem Saqib3†, Akshita K. Vincent1,
Amirthagowri Ambalavanan2,21, Falak Sher Khan3, Muhammad Ayaz4, Naseema Shaheen5, Dan Spiegelman2,21,
Ghazanfar Ali6, Muhammad Amin-ud-din7, Sandra Laurent2,21, Huda Mahmood1, Mehtab Christian2, Nadir Ali3,
Alanna Fennell1, Zohair Nanjiani8, Gerald Egger1,9, Chantal Caron10,11, Ahmed Waqas3, Muhammad Ayub4,12,
Saima Rasheed13, Baudouin Forgeot d’Arc10,11,14, Amelie Johnson11,14, Joyce So15,16,17, Muhammad Qasim Brohi18,
Laurent Mottron10,11,14, Muhammad Ansar3, John B Vincent1,19* and Lan Xiong2,11,14*Abstract
Background: Cohen Syndrome (COH1) is a rare autosomal recessive disorder, principally identified by ocular, neural
and muscular deficits. We identified three large consanguineous Pakistani families with intellectual disability and in
some cases with autistic traits.
Methods: Clinical assessments were performed in order to allow comparison of clinical features with other VPS13B
mutations. Homozygosity mapping followed by whole exome sequencing and Sanger sequencing strategies were
used to identify disease-related mutations.
Results: We identified two novel homozygous deletion mutations in VPS13B, firstly a 1 bp deletion, NM_017890.4:c.
6879delT; p.Phe2293Leufs*24, and secondly a deletion of exons 37-40, which co-segregate with affected status. In
addition to COH1-related traits, autistic features were reported in a number of family members, contrasting with
the “friendly” demeanour often associated with COH1. The c.6879delT mutation is present in two families from different
regions of the country, but both from the Baloch sub-ethnic group, and with a shared haplotype, indicating a founder
effect among the Baloch population.
Conclusion: We suspect that the c.6879delT mutation may be a common cause of COH1 and similar phenotypes
among the Baloch population. Additionally, most of the individuals with the c.6879delT mutation in these two families
also present with autistic like traits, and suggests that this variant may lead to a distinct autistic-like COH1 subgroup.Background
Intellectual disability (ID) affects ~1 % of the population
[1], however for up to 80 % of ID patients the underlying
etiology is unknown. Chromosomal aberrations are
thought to be the most common cause [2]. In a cohort
of 1170 unselected patients referred for developmental
delay or ID, Cohen syndrome (COH1) [MIM# 216550]* Correspondence: john.vincent@camh.ca; lan.xiong@umontreal.ca
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creativecommons.org/publicdomain/zero/1.0/was found among several common genetic diagnoses for
ID; and with a frequency of 0.7 %, COH1 is ranked right
after Fragile-X syndrome (1.2 %) among patients with
clear diagnosis of ID [2]. COH1 is an autosomal reces-
sively inherited ID disorder, first described by Cohen
and colleagues in 1973 [3]. Kivitie-Kallio and Norio [4]
proposed that the essential features for a COH1 diagno-
sis include non-progressive psychomotor retardation,
motor clumsiness, microcephaly, distinctive facial fea-
tures, childhood hypotonia, joint laxity, chorioretinal
dystrophy, myopia and granulocytopenia [4]. After muchcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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groups, newly amended diagnostic guidelines were given
in which a child with significant learning difficulties
must show at least two of the three features: typical facial
gestalt, pigmentary retinopathy or neutropenia [5, 6].
To date, COH1 has been mainly attributed to muta-
tions in the VPS13B gene (MIM# 607817) among pa-
tients from many different ethnic backgrounds [7–15].
For approximately 70 % of COH1 patients both mutated
alleles of VPS13B were detected, whereas in approximately
20-30 % of the cases a single heterozygous mutation was
found [8, 10]. A total of 159 VPS13B gene mutations
(HGMD, 2013.4) have been identified which have since led
to further modification of the clinical diagnostic criteria for
differentiation between Cohen and Cohen-like syndrome
[8, 14, 16–18]. In the present study, we describe the
ascertainment and clinical assessment of three large con-
sanguineous families from Pakistan segregating ID in an
autosomal recessive pattern. We also describe the map-
ping by autozygosity of the disease locus for each family
to 8q22, followed by screening and mutation detection
in VPS13B through either candidate gene sequencing or
whole exome sequencing.
Methods
Patients and families
Two of the Pakistani families (RQMR10 and ANMR51)
were initially identified through referral to the study on
genetics of autosomal recessive ID through collabora-
tions between the Lahore Institute of Research & Devel-
opment (LIRD), Pakistan, and the Centre for Addiction
& Mental Health (CAMH), Toronto, Canada, and be-
tween Quaid-i-Azam University, Islamabad and CAMH.
These two families are from Dera Ghazi Khan District,
Punjab Province, and from Naushahro Feroze district in
Sindh Province, respectively. The third Pakistani family
(ATM02) was identified and recruited as a recessive
form of pervasive developmental disorder (PDD) from
Dadu District, Sindh Province, through collaboration
between the Sir Cowasji Jehangir Institute of Psychiatry
(SCJIP), Hyderabad, Pakistan and CHUM Research
Center (CRCHUM), University of Montreal, Canada.
Research Ethics Board approval was obtained from the
involved institutions (LIRD, Quaid-i-Azam University,
CAMH, SCJIP and CRCHUM), and written informed
consent was obtained from the parents/guardians and
other family members for publication of this article and
any accompanying images, in compliance with the
Helsinki Declaration. The pedigrees (Fig. 1) were con-
structed by interviewing different family members. 293
healthy Pakistani controls were also recruited, after
written informed consent was given, so that variants
could be checked for frequency in an ethnically
matched population.Clinical investigation of families RQMR10 and ANMR51
All affected family members were examined clinically,
with special attention to neurological, psychological,
ophthalmological, skeletal, behavioral and dental anom-
alies. One affected member from RQMR10 family (VI-2)
was subjected to fundoscopic examination, in order to
investigate the ophthalmological condition associated
with the disease in that family. Complete biochemical
testing of blood of affected as well as several unaffected
individuals was performed for both families, in particular
to confirm or exclude neutropenia — one of the charac-
teristic features of COH1.
Clinical investigation of ATM02 family
The three affected brothers were examined by local cli-
nicians, including a psychiatrist, a clinical psychologist
and a neurologist, and evaluated retrospectively using
the Childhood Autism Rating Scale (CARS) [19]. One of
the affected individuals was also available for additional
clinical tests: including routine blood/urine test, bio-
chemistry test (serum TSH, B12 and folic acid, CPK, and
random blood glucose test) and brain MRI. Their clinical
synopsis, CARS ratings, lab test results and diagnosis have
been further reviewed and validated by three pediatric psy-
chiatrists (C.C., B.F.A., L.M.) from Montreal.
DNA extraction, genotyping, homozygosity mapping and
sequencing
Genomic DNA was extracted from either whole blood or
from saliva of affected and unaffected family members, by
following standard protocols. For RQMR10, DNA samples
from three affected (V-2, VI-2, VI-3) and two unaffected
individuals (V-3, V-4), were genotyped using the Affyme-
trix Genome-Wide Human SNP 6.0 microarray at The
Centre for Applied Genomics (TCAG), Toronto. DNA
samples from eight affected individuals (IV-3, IV-4, IV-5,
V-1, V-3, V-6, V-7, V-8) and one unaffected individual
(V-10) from ANMR51 were genotyped using the Affy-
metrixGeneChip Mapping 500 K NspI array, at the
London Regional Genomics Centre (LRGC, University
of Western Ontario). For ATM02, the three affected in-
dividuals (V-1, V-3, V-5) and four unaffected individuals
(IV-7, IV-8, V-4 and V-6) were genotyped using the Illu-
mina HumanOmniExpress BeadChip at the Genome
Quebec and McGill University Innovation Centre.
For RQMR10 and ANMR51 homozygosity-by-descent
(HBD) or autozygosity mapping and copy number vari-
ation (CNV) analysis was performed using dChip soft-
ware [20, 21]. For ATM02, KaryoStudio program from
Illumina Inc. was used to exclude cytogenetic abnormal-
ities, and HBD mapping was performed by using the
HomozygosityMapper [22].
For RQMR10 and ANMR51, direct Sanger sequencing
of VPS13B was performed, based on homozygosity
Fig. 1 Pedigrees of the three Pakistani families. For family RQMR10, although the degree of relatedness between the parents of V-1, V-2, and V-3
could not be established, marriages within this rural community are strictly within the clan system, and thus they are almost certainly related.
ATM02 is part of a much larger pedigree segregating ID, with 18 affected individuals, however only members of the portion indicated here was
assessed in this study. This full pedigree is shown in Additional files 1, 2, 3 and 4
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VPS13B. PCR primers were designed using Primer3 (ver-
sion 0.4.0). PCR amplicons were sequenced at TCAG.
Sequencing data were aligned to the annotated human
genome sequence (hg19) using the BLAT tool of the
UCSC Genome Browser, and variants confirmed by check-
ing the sequencing chromatograms. Once identified, the
inheritance pattern of the variant was checked across the
pedigree for cosegregation with the phenotype. Potential
candidate variants were further validated in Pakistani
population controls through Sanger sequencing.
For ATM02 family, whole exome capturing and se-
quencing in two affected individuals (V-1 and V-5) were
performed using Agilent SureSelect™ 50 Mb Human All
Exon Kit and sequenced by HiSeq2000 at the Genome
Quebec and McGill University Innovation Centre. Se-
quence data was processed and aligned using a bioinfor-
matic pipeline including FASTQC, BWA [23], GATK
[24] and ANNOVAR programs [25]. An in-house script
was created to generate familial variant segregation files.
Potential candidate variants were further validated in
additional family members, and Pakistani population
controls through Sanger sequencing.Deletion break-point mapping
A PCR-based approach was used in order to map the
deletion breakpoints in family ANMR51. Sets of primers
were designed using Primer 3 (Primer3 software, version
0.4.0) for regions flanking the putative deleted exons
(exons 37–40). PCR amplification was performed using
a forward primer from the closest proximal amplicon
and a reverse primer from the closest distal set that that
amplified in affected individuals, in order to identify the
junction fragment. The junction fragment was then
sequenced, and the exact physical co-ordinates were
mapped using the BLAT tool of the UCSC Genome
Browser.
Results
Clinical findings
Families RQMR10 and ANMR51 (Figure 1): All af-
fected, as well as several unaffected family members
were examined clinically, with special attention to pres-
ence or absence of microcephaly, short stature, speech
development, facial dysmorphisms, myopia, pigmentary
retinopathy, pes planus, pes cavus, neutropenia and
neuropsychiatric presentation, except for RQMR10
Rafiq et al. BMC Medical Genetics  (2015) 16:41 Page 4 of 10VI-1, who died of liver failure after joining the study, re-
sults shown in Table 1. Analysis of photographs (Fig. 2)
by a dysmorphologist (J.S.) indicated for RQMR10 af-
fected individuals having a boxy shaped face, straight
eyebrows, mild synophrys, hypoplastic nares, prominent
lips, and a small chin with mild prognathia (V-2, VI-3,
VI-2), left eye exotropia (V-2, VI-3), ptosis (VI-2), slender
nose with hypoplastic nares and a hanging columella
(V-2). VI-2 also shows patchy skin hyperpigmentation
over the temples, cheeks, nose, chin, and lateral aspects
of the face and neck. For family ANMR51 individuals V-
6 and V-7 have straight, bushy eyebrows with syno-
phrys, deep-set eyes, short philtrum, and thin lips. V-6
also has a large chin, prominent nasal bridge with hypo-
plastic nares, pointed nasal tip and hanging columella.
V-7 shows bilateral ptosis, exotropia, a broad nasal root
and bridge and nasal tip with hypoplastic nares and hang-
ing columella. Fundoscopy images for RQMR10
individual VI:2 were examined (E.H.), and showed ab-
normality compatible with a retinal dystrophy and with
Cohen syndrome. The optic nerves were pale and the
macular looked thinned and the blood vessels (arteri-
oles) are attenuated (see Additional file 1: Figure S1). Night
blindness and progressive vision loss were also observed
in the affected individuals.
Some autistic-like traits were observed in affected
members of RQMR10, who were reported to be aloof,
isolated and not sociable; however in the context of their
ID it was not possible to assess for autism spectrum dis-
order. No repetitive behaviors were noted. Based on
clinical interview, the level of ID was estimated as mod-
erate to severe in the affected individuals in RQMR10.
In regards to social functioning, one female (V-2) was
initially considered aloof, and later developed severe de-
pressive disorder. RQMR10 VI-2 is reported as being
hyperactive, having no sense of danger, and would fre-
quently wander away from home.
Family ATM02 (Figure 1) is part of a much larger pedi-
gree segregating with ID across many branches, with 18 af-
fected individuals (see Additional file 2: Figure S2). In this
study we were able to access just the portion of the family
shown in Fig. 1. Three affected brothers presented with
Cohen syndrome features (Table 1). In addition, individual
V-1 had normal blood and urine tests, except for blood
neutrophil at 2.0 × 10−9/L, and his brain MRI indicates
non-specific mild to moderate brain atrophy with enlarged
ventricles and subarachnoid spaces (see Additional file 3:
Figure S3). However, due to lack of information on neutro-
penia and retinopathy, the diagnosis of COH1 was not
made prior to the genetic investigation. They were all ini-
tially diagnosed with pervasive developmental disorder not
otherwise specified (PDD-NOS). Ophthalmological exam-
ination later confirmed that the three affected brothers all
present with pigmentary retinopathy.Head circumference measurements (occipito-frontal
circumference) were available for ANMR51 and ATM02,
and show measures consistently > 3SD below the mean,
suggesting that microcephaly is also a common feature
in these families (Table 1).Mutation Detection in RQMR10, ANMR51 and ATM02
families
RQMR10 Family
We identified only one ~25.430 Mb HBD region shared
by the affected individuals, but not unaffected family
members, on 8q22, flanked by SNPs rs1994035 and
rs3098237 in family RQMR10. Sanger sequence analysis
of all PCR amplicons revealed a deletion of 1 bp, T,
(Fig. 3) at position chr8:100,732,719 (hg19) on chromo-
some 8q22.2. This deletion, NM_017890.4:c.6879delT,
introduces a framseshift, resulting in premature protein
truncation (p.Phe2293Leufs*24). Exon38 of VPS13B was
sequenced in family members and in 293 normal unre-
lated healthy individuals from Pakistan. The homozy-
gous c.6879delT mutation cosegregates with the clinical
phenotype correctly within the family, and was not
present in 293 healthy Pakistani controls. The variant is
present as heterozygote in the Exome Aggregation Con-
sortium Browser (ExAC; Cambridge, MA; http://exac.-
broadinstitute.org; Oct 2014), which includes over 8,000
exomes from South Asian individuals, but only one out
of 122494 alleles total, and one out of 16,592 South
Asian alleles.ANMR51 Family
Analysis of genotypes for family ANMR51 revealed only
one ~4.413 Mb HBD region shared by the affected indi-
viduals, but not unaffected family members, on 8q22
flanked by SNPs rs11783149 and rs2679749. Four con-
secutive exons (37–40) failed to amplify by PCR, yet
amplified in unaffected family members, suggesting a
possible deletion. The deletion fragment was confirmed
and mapped by PCR amplification and sequencing of
the junction fragment (forward primer-VPS13B-JF-F-5′-
TCCTAAAATGTGCCA TTGGTT-3′; reverse primer-
VPS13B-JF-R: 5′-TGCTGAAGAATAGATTGCTGAA-3′)
(Fig. 3). Sequence analysis of the junction fragment
showed the deletion happens between chr8:100,728,884
and 100,779,911 (hg19), spanning a region of 51,027 bp
(hg19:g.chr8:100728884_chr8:100779911 del). Assum-
ing utilization of the same acceptor and donor splice
sites as for the wild type for the remaining part of the
gene, the deletion is predicted to lead to a truncated
protein, i.e., p.Gly2177Alafs*16. The deletion was co-
segregating as homozygous mutation within the family.
The deletion was not present in 293 unrelated healthy
Pakistani individuals.
Table 1 Clinical features of affected members of families ANMR51, RQMR10 and ATM02. n.a. = not assessed
Family ANMR51 RQMR10 ATM02
Patient ID IV-5 IV-4 IV-3 V-3 V-1 V-6 V-7 V-8 VI-2 VI-3 VI-1a V-2 V-1 V-3 V-5
Sex M M F M M M M F M F M F M M M
Age (Yrs) 25 27 17 20 15 >50 >50 >50 17 7 8 20 23 18 15
Neurodevelopment
Developmental delay
(motor, cognitive,
speech)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Intellectual Disability Severe Severe Severe Severe Severe Severe Severe Severe Severe Severe Severe Severe Moderate Moderate Moderate
Language Single
words
Single
words
Single
words
Single
words
Single
words
Single
words
Single
words
Single
words
Single words No
speech
Single
words
Single words Small
sentences
Small
sentences
Small
sentences
Autistic behaviors Nb Nb Nb Nb Nb Nb Nb Nb Nbc Nb Nb Y Y Y Y
Age 1st walked <2 <2 <2 <2 <2 <2 <2 <2 2 4 2 <2 2.5 2.4 2.0
Hypotonia? n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. yes yes yes
Coordination poor poor poor poor poor poor poor poor poor poor poor poor poor poor poor
Facies
OFC (cm) 49 49 47 n.a. n.a. 47.5 48 48 n.a. n.a. n.a. n.a. 51 49 49
Thick eyebrows n.a. n.a. n.a. n.a. n.a. No Yes n.a. Yes No n.a. No Yes Yes Yes
Prominent nasal
bridge
n.a. n.a. n.a. n.a. n.a. No Yes n.a. No No n.a. No Yes Yes Yes
short philtrum n.a. n.a. n.a. n.a. n.a. Yes Yes n.a. No No n.a. No Yes Yes Yes
wide or wave
shaped palpebral
fissures
n.a. n.a. n.a. n.a. n.a. Yes No n.a. No No n.a. No Yes Yes Yes
Prominent incisors n.a. n.a. n.a. n.a. n.a. n.d. n.d. n.a. Yes Yes n.a. Yes Yes Yes Yes
Mild synophrys n.a. n.a. n.a. n.a. n.a. Yes Yes n.a. Yes Yes n.a. Yes Yes Yes Yes
Eyes
Myopia + + + + + Blind Blind + + + + + + + +
Retinopathy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. + retinal
dystrophy
n.a. n.a. n.a. n.a. n.a. n.a.
Neutropenia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. - Pan-
cytopenia
n.a. n.a. + n.a. n.a.
Miscellaneous Total loss
of teeth
- Prominent
chin
- - Ptosis;
hyperactivity
Pes planus &
pes cavus;
Truncal obesity
Pes planus
hypoactive
Pes planus
hyperactive
recurrent skin
infections
Pes planus;
pica
aNow deceased
bthese individuals were aloof, isolated, not sociable; however there were no repetitive behaviors
cHyperactivity also noted
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Fig. 2 Photos of affected individuals from the three families
Rafiq et al. BMC Medical Genetics  (2015) 16:41 Page 6 of 10ATM02 family
Homozygosity mapping identified four HBD regions
shared in three affected individuals: 1p36.32-p36.31
(rs10799181 to rs9308476, 1.87 Mb); 1p13.2-q21.3
(rs11804649 to rs6655975, 37.19 Mb), 8q21.11-q24.21
(rs7824974 to rs4407842, 52.49 Mb), and 16p13.
3-p12.1 (rs2541696 to rs8047869, 24.27 Mb). Exome
sequencing and analysis of two affected individuals (V1
and V5) led to the identification of the same 1 bp
homozygous deletion at c.6879 T found in RQMR10. In
the meantime, we have excluded any additional loss of
function variant(s) (both homozygote and heterozy-
gote) in genes known to carry pathogenic mutations for
ID and ASD (SFARI gene list), in the two affected indi-
viduals, separately and jointly. The deletion at c.6879 T
was confirmed by Sanger sequencing as homozygous in
three affected individuals, but absent in unaffected
family members and 293 controls, as mentioned for
RQMR10.
Haplotype sharing between RQMR10 and ATM02
Interestingly, RQMR10 and ATM02 were found to carry
the same c.6879delT mutation independently. Subsequent
joint analysis of shared HBD regions showed that among
592 common SNPs shared between Affymetrix and Illu-
mina SNP chips within the overlapping HBD region on
chr 8q22.2 in both families, 208 SNPs from a 2.14 Mb
region showed the same haplotype (see in Fig. 4, also
Additional file 4: Table S1), indicating a founder effect of
this mutation within the population of Pakistan. Neitherfamily is aware of any common ancestry, and has lived in
regions separated by a distance of 534 km, although both
are from the Baloch ethnic group. Based on the size of
shared haplotype, the two families may share common an-
cestors approximately 50 generations ago (mean distance
between the nearest flanking crossovers of the disease
locus is 2/N morgans, where N is the number of meioses)
[26].
Discussion
We present a study of three large consanguineous Paki-
stani families with autosomal recessive ID and in some
cases autistic behaviors, segregating with deletion muta-
tions within the VPS13B gene. This large gene, spanning
a region of 864 Kb with 62 exons, maps to chromosome
8q22.2 [7, 8]. The gene encodes a protein of 4,022 amino
acids (plus a number of shorter isoforms) with several
short regions showing homology with yeast vacuolar
protein sorting-associated protein 13 (Vps13b), suggest-
ing a possible role in vesicle-mediated protein sorting
(VPS) and intracellular protein transportation [13, 14,
27, 28]. Functional studies show evidence for VPS13B
co-localizes strongly with the cis-Golgi matrix protein
GM130 [29]. The study also showed that VPS13B/
COH1 is required for the maintenance of Golgi stacks as
well as for reassembly of Golgi cisternae from minis-
tacks, and can regulate the formation of membrane tu-
bules from the Golgi. These functions suggest similarity
with Golgins (Golgi autoantigens), except that VPS13B/
COH1 does not contain coiled-coil domains. Absence or
Fig. 3 a Ideogram of chromosome 8, indicating location of HBD at 8q22. b Genomic organization of VPS13B/COH1, indicating location of the
NM_017890.4:c.6879delT mutation (RQMR10 and ATM02) in exon 38, as well as the deleted region (exons 37–39) in ANMR51. c Electropherograms
indicating the wild type homozygous (top), heterozygous (middle) and mutant homozygous (bottom) sequence across NM_017890.4:c.6879
(RQMR10 and ATM02). d Electropherogram from mRNA sequencing from an affected individual from ANMR51, indicating the (aberrant) splicing
of exons 36 and 40
Rafiq et al. BMC Medical Genetics  (2015) 16:41 Page 7 of 10depletion of VPS13B/COH1 could lead to disruption in
the Golgi complex integrity and functionality [29]. More
recent work further demonstrated that VPS13B mutations,
responsible for COH1, are associated with strong protein
glycosylation defects, highlighting an important role for
VPS13B in Golgi glycosylation and morphology, as well as
in lysosomal–endosomal pathway maintenance [30].
The first mutation we report, a 51 Kb homozygous
deletion encompassing four coding exons, assuming
correct splicing of the flanking exons 36 to 41 during
RNA maturation and processing, 793 bp of coding se-
quence would be deleted, leading to a shift in readingframe, with the substitution glycine to alanine at amino
acid 2177, followed by a premature stop codon after a
further 14 residues, leading to a 2191 amino acid residue
protein (compared to 4022 for wild type, NM_017890).
This premature stop codon would either lead to
nonsense-mediated mRNA decay (NMD) or production
of a truncated protein lacking a number of functional
domains. This potential shortened protein (p.Gly2177A-
lafs*16) would lack domains DUF1162 and ATG_C
(using SMART). The genomic region of the deletion
contains no known segmental duplications, large repeats
or other sequences that may be likely to predispose
Fig. 4 Homozygosity by descent of the Pakistani families and shared haplotype region for RQMR10 and ATM02. The homozygous-by-descent
regions segregating with the phenotype within families RQMR10, ATM02 and ANMR51 are indicated with a dark blue, a green and a purple bar,
respectively. The red bar indicates the region of shared haplotype for families RQMR10 and ATM02 and spans the entire VPS13B
Rafiq et al. BMC Medical Genetics  (2015) 16:41 Page 8 of 10towards genomic instability (UCSC Genome Browser,
hg19), and no CNVs have been identified at this region,
according to the Database of Genomic Variants.
The 1 bp deletion at c.6879 T [NM_017890.4 (VPS13B_
v001):c.6879delT], leads to a shift in frame and a premature
stop codon (PTC) after amino acid 2315 (p.Phe2293-
Leufs*24). This premature stop codon would also either
lead to NMD or production of nonfunctional protein. The
truncated protein would lack many of the main predicted
functional domains of the VPS13B protein, including Pfam
predicted domains DUF1162 and ATG_C.
Since the two mutations would have a very similar
functional effect, with truncation at similar points along
the protein (2191 residues for RQMR10 and ATM02
mutation; 2315 residues for ANMR51 mutation), one
might expect the resulting phenotype to be very similar.
However, the affected individuals from these three fam-
ilies showed remarkable phenotypic variations, which
could be due to other factors, including the degree of
NMD that may occur for the two mutations, which in
itself may depend on the nucleotide context of the
premature stop codon and the assembly of the NMD
complex [31]. Interestingly, most affected members of
the two families with the c.6879delT mutation were
either evaluated as having autism spectrum disorder
(ASD) or of possessing autistic-like traits. Mutations inVPS13B have recently been found in additional cases of
ASD or ID individuals with autistic features. Yu et al. in
a study of 163 consanguineous and/or multiplex families
with ASD through exome sequencing, found a homozy-
gous frameshift mutation (Ser3945Glnfs*22) in a pro-
band with ASD and mild dysmorphic features, as well as
a rare missense mutation (p.S824A) in a proband with
autism and mild facial dysmorphism and joint laxity
[32]. In the same study, screening VPS13B gene in 612
families from the Simons Simplex Collection, one affected
male child with ASD was found to be compound heterozy-
gous for two different mutations in VPS13B (p.W963*/
p.G2704R), and a second, unrelated male child affected
with autism was compound heterozygous for two rare point
mutations in VPS13B, p.S3303R and p.A3691T, both alter-
ing highly conserved residues of VPS13B [32]. Re-analyzing
exome sequencing data of 488 ASD cases and 372 con-
trols from the ARRA Autism Sequencing Collaboration
(AASC) project, Ionita-Laza I et al. found two loss-of-
function variants (one nonsense: p.Ser3383* and one
splice site: c:2650 + 2 T > G), and a rare, homozygous
probably-damaging variant (p.Arg3198Trp) in VPS13B
that could contribute to autism risk [33]. Although only
a single previous report of VPS13B mutations and
COH1 in individuals of Pakistani origin has been pub-
lished [34], identification of three unrelated large families
Rafiq et al. BMC Medical Genetics  (2015) 16:41 Page 9 of 10from Pakistan carrying homozygous mutations in VPS13B
indicates that this is an important gene, not only for
COH1, but also for undiagnosed or misdiagnosed ID
and ASD patients, in the Pakistani population. We
believe that Cohen syndrome individuals with this
“Baloch” variant may be enriched for ASD or autistic-like
behaviors, which contrasts with the “friendly disposition”
frequently associated with COH1. Early genetic screen for
the extended families or clans, and local communities
would be extremely useful in genetic counseling, and
clinical diagnosis.Conclusion
We suspect that the c.6879delT mutation may be a com-
mon cause of COH1 and similar phenotypes among the
Baloch population. Additionally, most of the individuals
with the c.6879delT mutation in these two families also
present with autistic like traits, and suggests that this vari-
ant may lead to a distinct autistic-like COH1 subgroup.Bioinformatic resources
1. Primer3 software (version 0.4.0): http://frodo.
wi.mit.edu/primer3/
2. UCSC Genome Browser: http://genome.ucsc.edu/
3. Exome Aggregation Consortium browser (ExAC;
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